01951 JXR
- 3.110
- -0.040-1.27%
JXR News
HKEX News | JXR (01951) up more than 5% in the afternoon, encouraging childbirth and assisted reproduction are continuously catalyzed by the inclusion of medical insurance policies.
Shares of Jxr (01951) rose more than 5% this afternoon. As of press time, it rose 4.61% to HKD 3.18 with a trading volume of HKD 29.177 million.
HK stocks surge | JXR (01951) rises nearly 6%, domestic policies continue to catalyze, and the assisted reproduction industry is expected to rebound in business activity.
According to the app of Zhitong Finance, JXR (01951) rose nearly 6%, rising 5.96% to HKD 3.38 as of press time, with a turnover of HKD 54.93 million. In order to implement positive fertility support measures, the Shanghai Medical Insurance Bureau, together with the Human Resources and Social Security and Health Departments, issued the "Notice on Including Some Therapeutic Assisted Reproductive Technology Projects in the Scope of Medical Insurance and Work Injury Insurance Payment", which will include 12 assisted reproductive medical services projects in the scope of medical insurance payment. It will be implemented from June 1, 2024. According to incomplete statistics, as of now, Beijing, Guangxi, Inner Mongolia
錦欣生殖：股東週年大會通告
Retail Investors Among Jinxin Fertility Group Limited's (HKG:1951) Largest Stockholders and Were Hit After Last Week's 8.2% Price Drop
Key Insights The considerable ownership by retail investors in Jinxin Fertility Group indicates that they collectively have a greater say in management and business strategy The top 25 shareholders
[Broker Focus] CITIC Construction Investment maintains Jinxin Reproduction (01951) “buy” rating. Looking at the short term, relevant policies will increase the penetration rate of assisted reproductive technology
Jinwu Financial News | According to CITIC Construction Investment Securities Research, Jinxin Production (01951) achieved revenue of 2,789 million yuan in 2023, up 18% year on year; net profit of 347 million yuan, up 194% year on year; adjusted net profit of 472 million yuan, up 72% year on year; and basic earnings per share of 0.13 yuan/share. According to the bank, the company's 2023 performance is in line with expectations, and demand for assisted reproductive technology and services has resumed. Looking ahead to 2024, domestic policies to encourage childbearing and the inclusion of assisted reproduction in health insurance will continue to be catalyzed, and industry sentiment is expected to pick up further; the company will use Chengdu as a model to create assisted reproduction
Changes in Hong Kong stocks | Jinxin Reproduction (01951) is now up nearly 5%, Shanghai includes 12 assisted reproductive technologies in medical insurance payments
Jinxin Reproduction (01951) is now up nearly 5%. As of press release, it has risen 4.95% to HK$3.39, with a turnover of HK$119 million.
Changes in Hong Kong stocks | Jinxin Reproduction (01951) rose more than 8%. With favorable policies in various regions gradually advancing, the prosperity of the assisted reproduction industry is expected to pick up
Jinxin Reproduction (01951) rose more than 8%. As of press release, it rose 8.25% to HK$3.28, with a turnover of HK$151 million.
Investors Appear Satisfied With Jinxin Fertility Group Limited's (HKG:1951) Prospects As Shares Rocket 25%
Despite an already strong run, Jinxin Fertility Group Limited (HKG:1951) shares have been powering on, with a gain of 25% in the last thirty days. Not all shareholders will be feeling jubilant, sin
Changes in Hong Kong stocks | Jinxin Reproduction (01951) rose more than 10% The National Health and Health Commission will introduce fertility support policies at a press conference in the afternoon
The Zhitong Finance App learned that Jinxin Reproduction (01951) rose by more than 10%. As of press release, it had risen 9.89% to HK$3, with a turnover of HK$804.516 million. According to the news, the National Health Commission will hold a press conference at 3 p.m. this afternoon to introduce “implementing the requirements for high-quality population development and actively constructing a fertility support policy system.” Haitong International previously stated that China's assisted reproduction market has broad prospects. With the increase in the number of elderly mothers in China and the gradual advancement of measures such as active childbearing encouragement policies and inclusion in health insurance, the boom in China's ARS industry is expected to pick up. Up to now, Beijing and Guangxi
We Think Jinxin Fertility Group (HKG:1951) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
錦欣生殖：2023年報
Is Now The Time To Look At Buying Jinxin Fertility Group Limited (HKG:1951)?
Jinxin Fertility Group Limited (HKG:1951), is not the largest company out there, but it saw significant share price movement during recent months on the SEHK, rising to highs of HK$2.84 and falli
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Changes in Hong Kong stocks | Jinxin Reproduction (01951) rose by more than 6%, and assisted reproduction was included in health insurance companies in many places to expand the assisted reproduction market in Southeast Asia
Jinxin Reproduction (01951) rose more than 6%. As of press release, it rose 6.17% to HK$2.58, with a turnover of HK$29.36,500.
[Hong Kong Stock Connect] Jinxin Reproduction (01951) rose 5.76%, Citi says its valuation is still attractive
Jinwu Financial News | Jinxin Reproduction (01951) stock price fluctuated and rose in early trading. As of press release, it had risen 5.76% to HK$2.57. According to the news, on April 1, Jinxin Reproductive Medical Group Co., Ltd. announced the signing of an equity investment agreement with PT Morula Indonesia. Jinxin Fertility said that after the investment is completed, Jinxin Fertility will become Morula's largest strategic investor. At the same time, the two sides will reach strategic cooperation, achieve resource integration, and work together to develop the assisted reproduction industry market in Indonesia and Southeast Asia. Citi released a research report saying that it will maintain Jinxin Reproduction's “buy” rating and consider
Jinxin Reproduction (01951.HK) and Indonesia's Morula reached an equity strategic investment cooperation to expand the assisted reproduction market in Southeast Asia
On April 1, 2024, Jinxin Reproductive Medicine Group Co., Ltd. (01951.HK) announced the signing of an equity investment agreement with Indonesia's PT Morula Indonesia (“Morula”). After the investment is completed, Jinxin Fertility will become Morula's largest strategic investor. At the same time, the two sides will reach strategic cooperation, achieve resource integration, and jointly explore the assisted reproduction industry market in Indonesia and Southeast Asia. The population of Southeast Asia is huge and continues to grow. At the same time, with economic development, residents' consumption capacity is also increasing, and the assisted reproduction industry has great potential for growth.
Open Source Securities: Maintaining Jinxin Reproduction's (01951) “Buy” rating, Shenzhen's new hospital is expected to be put into operation
Open Source Securities estimates that Jinxin Reproduction (01951)'s net profit for 2024-26 will be $3.87/46,538 million yuan.
Jinxin Fertility Logs 185% Profit Surge in 2023 as Revenue Rises 18%
Jinxin Fertility Group (HKG:1951) recorded a 184.6% rise in attributable profit for the year ended Dec. 31, 2023, to 344.7 million yuan from 121.1 million yuan in 2022, a filing posted on the Hong Kon
Understand the 2023 annual results highlights of Jinxin Reproduction (01951.HK) in one picture
On March 27, Jinxin Reproduction (01951.HK) announced the results for the year ended December 31, 2023. We will take you to understand the specific results in a chart.
Jinxin Reproduction (1951.HK): Remarkable results after the epidemic, with both high growth and certainty, the right time to invest
In 2023, the birth rate of China's population continued to decline and experienced negative population growth for the first time. Against this backdrop, “Jinxin Reproduction”, the first stock of assisted reproduction, announced financial results for the fiscal year 2023, achieving operating income of 2.79 billion yuan, an increase of 18% over the previous year. Its net profit and adjusted net profit reached 350 million yuan and 470 million respectively, achieving significant increases of 194% and 72% respectively compared to 2022, and even surpassed pre-pandemic levels. At the same time, the company also provided a cash dividend of about HK$164 million, and the dividend payment rate reached 43%.
Analysis
Price Target
No Data
